Although data suggest that anti-vascular endothelial growth factor injections work well for most, but not all, patients with diabetic macular edema (DME), real-world evidence indicates that outcomes fall far short of those seen in studies. While steroids like dexamethasone and fluocinolone—both available as implants—are used as alternatives, real-world evidence to support positive outcomes in the Fluocinolone Acetonide in Diabetic Macular Edema (FAME) trials are lacking. To assess whether FAME findings could be reproduced in clinical practice, investigators analyzed data from patients with 3 years of follow-up after flucinolone acetonide (FAc) implant therapy. Similar outcomes were observed as those seen in FAME, with visual acuity (VA) stabilized or improved in 71% of eyes and 20/40 vision achieved in 32% of eyes. No significant deterioration during the 3 years was seen in eyes that started with a VA of 20/40, and eyes with a shorter duration of disease showed greater improvements in VA. Safety data were similar with those in FAME.
September 8, 2020
ASTRO 2020: Stereotactic Radiosurgery Bests Whole-Brain Radiation Therapy for “Numerous” Brain Metastases
October 29, 2020
- ACC 2020The American College of Cardiology decided to cancel ACC.20/WCC due to COVID-19, which was scheduled to take place March 28-30 in Chicago. However, ACC.20/WCC Virtual Meeting continues to release cutting edge science and practice changing updates for cardiovascular professionals on demand and free through June 2020.
- ENDO: 2020ENDO 2020 Annual Conference has been canceled due to COVID-19. Here are highlights of emerging data that has still been released. Keep an eye out for ENDO Online 2020, which will take place from June 8 to 22.
- CROI 2020Every year, CROI hosts some of the world's leading experts in HIV research, who come to present exciting new data and drive forward the field of HIV/AIDS research. This year, due to COVID-19, CROI held their meeting virtually.